Accessibility navigation

Computational pharmacology: new avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises

Kanapeckaitė, A., Mažeikienė, A., Geris, L., Burokienė, N., Cottrell, G. S. ORCID: and Widera, D. ORCID: (2022) Computational pharmacology: new avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises. Biophysical Chemistry, 290. 106891. ISSN 0301-4622

[img] Text - Accepted Version
· Restricted to Repository staff only until 11 September 2024.
· Available under License Creative Commons Attribution Non-commercial No Derivatives.


It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1016/j.bpc.2022.106891


The COVID-19 pandemic created an unprecedented global healthcare emergency prompting the exploration of new therapeutic avenues, including drug repurposing. A large number of ongoing studies revealed pervasive issues in clinical research, such as the lack of accessible and organised data. Moreover, current shortcomings in clinical studies highlighted the need for a multi-faceted approach to tackle this health crisis. Thus, we set out to explore and develop new strategies for drug repositioning by employing computational pharmacology, data mining, systems biology, and computational chemistry to advance shared efforts in identifying key targets, affected networks, and potential pharmaceutical intervention options. Our study revealed that formulating pharmacological strategies should rely on both therapeutic targets and their networks. We showed how data mining can reveal regulatory patterns, capture novel targets, alert about side-effects, and help identify new therapeutic avenues. We also highlighted the importance of the miRNA regulatory layer and how this information could be used to monitor disease progression or devise treatment strategies. Importantly, our work bridged the interactome with the chemical compound space to better understand the complex landscape of COVID-19 drugs. Machine and deep learning allowed us to showcase limitations in current chemical libraries for COVID-19 suggesting that both in silico and experimental analyses should be combined to retrieve therapeutically valuable compounds. Based on the gathered data, we strongly advocate for taking this opportunity to establish robust practices for treating today’s and future infectious diseases by preparing solid analytical frameworks.

Item Type:Article
Divisions:Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
ID Code:107173

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation